MPS 2021 – Denali disappoints in Hunter syndrome
The group will need longer-term data to justify its huge valuation.
ISTH 2021 – Blackstone’s Novartis spin-out scores
Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
Lilly’s Protomer deal shows innovation in diabetes is not dead
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Arrowhead pause raises more questions about lung delivery
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
